Abnormal bone remodelling and increased levels of macrophage inflammatory protein‐1 alpha (MIP‐1α) in Waldenström macroglobulinaemia

Summary Serum levels of macrophage inflammatory protein‐1 alpha (MIP‐1α) and bone remodelling markers were evaluated in 38 patients with Waldenström macroglobulinaemia (WM) and correlated with clinical and laboratory variables. MIP‐1α was elevated in WM; untreated patients had higher MIP‐1α levels t...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2006-05, Vol.133 (3), p.301-304
Main Authors: Terpos, Evangelos, Anagnostopoulos, Athanasios, Kastritis, Efstathios, Bamias, Aristotelis, Tsionos, Konstantinos, Dimopoulos, Meletios‐Athanassios
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
beta 2-Microglobulin - blood
Biological and medical sciences
Biomarkers - blood
bone markers
Bone Remodeling
Bone Resorption - blood
Bone Resorption - etiology
Chemokine CCL3
Chemokine CCL4
Female
Hematologic and hematopoietic diseases
Humans
Immunodeficiencies. Immunoglobulinopathies
Immunoglobulinopathies
Immunopathology
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Macrophage Inflammatory Proteins - blood
macrophage inflammatory protein‐1 alpha
Male
Medical sciences
Middle Aged
osteoprotegerin
receptor activator of nuclear factor‐κB ligand
Splenomegaly - blood
Splenomegaly - etiology
Waldenstrom Macroglobulinemia - blood
Waldenstrom Macroglobulinemia - complications
Waldenström macroglobulinaemia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Serum levels of macrophage inflammatory protein‐1 alpha (MIP‐1α) and bone remodelling markers were evaluated in 38 patients with Waldenström macroglobulinaemia (WM) and correlated with clinical and laboratory variables. MIP‐1α was elevated in WM; untreated patients had higher MIP‐1α levels than patients in remission or with active disease after treatment. MIP‐1α correlated with increased bone resorption, β2‐microglobulin and splenomegaly. Receptor activator of nuclear factor‐κB ligand serum levels were elevated in WM patients; the subsequent increased bone resorption was balanced by a comparable elevation of osteoprotegerin production and bone formation. These findings may explain the absence of lytic lesions in WM patients and suggest a potential role of MIP‐1α in WM.
ISSN:0007-1048
1365-2141
DOI:10.1111/j.1365-2141.2006.06017.x